<- Go Home
Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Market Cap
$509.4M
Volume
663.8K
Cash and Equivalents
$96.7M
EBITDA
-$171.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$3.3M
Profit Margin
100.00%
52 Week High
$33.68
52 Week Low
$7.25
Dividend
N/A
Price / Book Value
1.68
Price / Earnings
-3.23
Price / Tangible Book Value
1.68
Enterprise Value
$215.9M
Enterprise Value / EBITDA
-1.26
Operating Income
-$172.0M
Return on Equity
41.83%
Return on Assets
-27.76
Cash and Short Term Investments
$294.6M
Debt
$1.1M
Equity
$304.0M
Revenue
$3.3M
Unlevered FCF
-$90.3M
Sector
Biotechnology
Category
N/A